在“Elsevier电子期刊”中,命中:252条,耗时:小于0.01 秒
1.Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis
刊名:Multiple Sclerosis and Related Disorders
出版年:2017
3.Randomized trial of rATg/Daclizumab vs. rATg/Alemtuzumab as dual induction therapy in renal transplantation: Results at 8 years of follow-up
刊名:Transplant Immunology
出版年:2017
6.Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies
作者:Gavin Giovannonia ; g.giovannoni@qmul.ac.uk" class="auth_mail" title="E-mail the corresponding author ; Ludwig Kapposb ; ludwig.kappos@usb.ch" class="auth_mail" title="E-mail the corresponding author ; Ralf Goldc ; Ralf.Gold@ruhr-uni-bochum.de" class="auth_mail" title="E-mail the corresponding author ; Bhupendra O Khatrid ; bokhatri@aol.com" class="auth_mail" title="E-mail the corresponding author ; Krzysztof Selmaje ; kselmaj@afazja.am.lodz.pl" class="auth_mail" title="E-mail the corresponding author ; Kimberly Umansf ; kim.umans@biogen.com" class="auth_mail" title="E-mail the corresponding author ; Steven J Greenbergg ; steven.greenberg@abbvie.com" class="auth_mail" title="E-mail the corresponding author ; Marianne Sweetserf ; 1 ; msweetser@alnylam.com" class="auth_mail" title="E-mail the corresponding author ; Jacob Elkinsf ; jake.elkins@biogen.com" class="auth_mail" title="E-mail the corresponding author ; Peter McCroskeryf ; peter.mccroskery@biogen.com" class="auth_mail" title="E-mail the corresponding author
刊名:Multiple Sclerosis and Related Disorders
出版年:2016
1
2
3
4
5
6
7
8
9
按检索点细分(252)
题名(120)
关键词(24)
文摘(175)
按出版年细分(252)
2027年及以后(3)
2017年(3)
2016年(5)
2015年(3)
2013年(9)
2012年(9)
2011年(16)
2010年(12)
2009年(15)
2008年(13)
2007年(16)
2006年(27)
2005年(54)
2004年(9)
2003年(21)
2002年(13)
2001年(13)
2000年(6)
2000年及以前(5)
NGLC 2004-2010.National Geological Library of China All Rights Reserved.
Add:29 Xueyuan Rd,Haidian District,Beijing,PRC. Mail Add: 8324 mailbox 100083
For exchange or info please contact us via email.